Thursday, June 23, 2011
Deal with it
In contrast to DPAc-through which GSK will cherry-pick
research from around the globe-the pharma's deal with MaRS gives it rights of
first refusal to a selection of early technologies emerging from MaRS' partner
institutions in Ontario.
Haas, M.J. SciBX 4(25); doi:10.1038/scibx.2011.700
Published online June 23, 2011
AND INSTITUTIONS MENTIONED
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
MaRS Innovation, Toronto, Ontario, Canada
University of Dundee, Dundee, U.K.